{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:14:43Z","timestamp":1789071283975,"version":"build-2803163510"},"reference-count":99,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Systemic JIA (SJIA) is distinguished from other forms of JIA by the prevalence of the severe, life-threatening complications macrophage activation syndrome (SJIA-MAS) and lung disease (SJIA-LD). Alternative therapeutics are urgently needed, as disease pathogenesis diverges from what is observed in SJIA, and currently available biologics are insufficient. SJIA-MAS, defined by a cytokine storm and dysregulated proliferation of T-lymphocytes, and SJIA-LD which presents with lymphocytic interstitial inflammation and pulmonary alveolar proteinosis, are both thought to be driven by IFNs, in particular the type II IFN-\u03b3. Involvement of IFNs and a possible crosstalk of type I IFNs with existing biologics indicate a distinct role for the JAK-STAT signalling pathway in the pathogenesis of SJIA-MAS and SJIA-LD. Here, we review this role of JAK-STATs and IFNs in SJIA complications and discuss how new insights of ongoing research are shaping future therapeutic advances in the form of JAK inhibitors and antibodies targeting IFNs.<\/jats:p>","DOI":"10.1093\/rheumatology\/keab673","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T09:51:20Z","timestamp":1630317080000},"page":"926-935","source":"Crossref","is-referenced-by-count":44,"title":["Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA)"],"prefix":"10.1093","volume":"61","author":[{"given":"Emely L","family":"Verweyen","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Cincinnati Children's Hospital Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant S","family":"Schulert","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Cincinnati Children's Hospital Medical Center"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine , Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"key":"2023011114285759500_keab673-B1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/annrheumdis-2018-214354","article-title":"Machine learning identifies an immunological pattern associated with multiple juvenile idiopathic arthritis subtypes","volume":"78","author":"Nieuwenhove","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023011114285759500_keab673-B2","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","article-title":"Juvenile idiopathic arthritis","volume":"377","author":"Prakken","year":"2011","journal-title":"Lancet"},{"key":"2023011114285759500_keab673-B3","first-page":"390","article-title":"International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis\u2009: second Revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2023011114285759500_keab673-B4","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/art.41073","article-title":"Systemic juvenile idiopathic arthritis\u2013associated lung disease: characterization and risk factors","volume":"71","author":"Schulert","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2023011114285759500_keab673-B5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/gene.2012.3","article-title":"Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment","volume":"13","author":"Ravelli","year":"2012","journal-title":"Genes Immun"},{"key":"2023011114285759500_keab673-B6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-020-0371-y","article-title":"Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases","volume":"16","author":"Hardy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2023011114285759500_keab673-B7","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/14712598.2020.1733524","article-title":"Current and emerging biologics for the treatment of juvenile idiopathic arthritis","volume":"20","author":"Cimaz","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2023011114285759500_keab673-B8","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1056\/NEJM199204163261602","article-title":"Methotrexate in resistant juvenile rheumatoid arthritis- results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial","volume":"326","author":"Giannini","year":"1992","journal-title":". N Engl J Med"},{"key":"2023011114285759500_keab673-B9","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F","article-title":"Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis","volume":"43","author":"Woo","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2023011114285759500_keab673-B10","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/BOR.0000000000000526","article-title":"Systemic juvenile idiopathic arthritis and macrophage activation syndrome","volume":"30","author":"Yasin","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"2023011114285759500_keab673-B11","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"2023011114285759500_keab673-B12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clim.2018.10.016","article-title":"Targeting cytokines to treat autoinflammatory diseases","volume":"206","author":"Hausmann","year":"2019","journal-title":"Clin Immunol"},{"key":"2023011114285759500_keab673-B13","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.pcl.2018.04.005","article-title":"Systemic juvenile idiopathic arthritis","volume":"65","author":"Lee","year":"2018","journal-title":"Pediatr Clin North Am"},{"key":"2023011114285759500_keab673-B14","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/art.40865","article-title":"Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study","volume":"71","author":"Haar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2023011114285759500_keab673-B15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-020-02303-y","article-title":"Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials","volume":"22","author":"Malattia","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2023011114285759500_keab673-B16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/acr.23853","article-title":"Long-term outcomes in juvenile idiopathic arthritis: eighteen years of follow-up in the population-based Nordic Juvenile Idiopathic Arthritis Cohort","volume":"72","author":"Glerup","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2023011114285759500_keab673-B17","first-page":"3727","article-title":"Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience","volume":"59","author":"Chhabra","year":"2020","journal-title":"Revmatol"},{"key":"2023011114285759500_keab673-B18","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1136\/annrheumdis-2018-213150","article-title":"Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials","volume":"77","author":"Ruperto","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023011114285759500_keab673-B19","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/annrheumdis-2019-216040","article-title":"Emergent high fatality lung disease in systemic juvenile arthritis","volume":"78","author":"Saper","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023011114285759500_keab673-B20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer","volume":"368","author":"O'Shea","year":"2013","journal-title":"N Engl J Med"},{"key":"2023011114285759500_keab673-B21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3389\/fimmu.2017.00029","article-title":"Canonical and non-canonical aspects of JAK-STAT signaling: lessons from interferons for cytokine responses","volume":"8","author":"Majoros","year":"2017","journal-title":"Front Immunol"},{"key":"2023011114285759500_keab673-B22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"2023011114285759500_keab673-B23","doi-asserted-by":"crossref","first-page":"7749","DOI":"10.1128\/JVI.02438-06","article-title":"Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases","volume":"81","author":"Zhou","year":"2007","journal-title":"J Virol"},{"key":"2023011114285759500_keab673-B24","first-page":"e23931","article-title":"Transcriptional regulation by STAT1 and STAT2 in the interferon JAK-STAT pathway","volume":"2","author":"Au-Yeung","year":"2013","journal-title":"JAKSTAT"},{"key":"2023011114285759500_keab673-B25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.immuni.2006.08.014","article-title":"Complex modulation of cell type-specific signaling in response to type I interferons","volume":"25","author":"van Boxel-Dezaire","year":"2006","journal-title":"Immunity"},{"key":"2023011114285759500_keab673-B26","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/cr.2008.41","article-title":"Roles of unphosphorylated STATs in signaling","volume":"18","author":"Yang","year":"2008","journal-title":"Cell Res"},{"key":"2023011114285759500_keab673-B27","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.2337\/diabetes.48.11.2166","article-title":"Heterophile anti-mouse immunoglobulin antibodies may interfere cytokine measurements in patients with HLA alleles protective for type 1a diabetes","volume":"48","author":"Redondo","year":"1999","journal-title":"Diabetes"},{"key":"2023011114285759500_keab673-B28","first-page":"1077","article-title":"Methods for type I interferon detection and their relevance for clinical utility and improved understanding of rheumatic diseases","volume":"37","author":"Lamot","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2023011114285759500_keab673-B29","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/jlb.61.3.246","article-title":"Mig and IP-10: CXC chemokines that target lymphocytes","volume":"61","author":"Farber","year":"1997","journal-title":"J Leukoc Biol"},{"key":"2023011114285759500_keab673-B30","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood-2006-08-040337","article-title":"TLR agonists induce regulatory dendritic cells to recruit Th1 cells via preferential IP-10 secretion and inhibit Th1 proliferation","volume":"109","author":"Qian","year":"2007","journal-title":"Blood"},{"key":"2023011114285759500_keab673-B31","doi-asserted-by":"crossref","first-page":"22878","DOI":"10.1074\/jbc.271.37.22878","article-title":"Characterization of \u03b2-R1, a gene that is selectively induced by interferon \u03b2 (IFN-\u03b2) compared with IFN-\u03b1","volume":"271","author":"Rani","year":"1996","journal-title":"J Biol Chem"},{"key":"2023011114285759500_keab673-B32","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"key":"2023011114285759500_keab673-B33","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/icb.2010.158","article-title":"CXCR3 ligands: redundant, collaborative and antagonistic functions","volume":"89","author":"Groom","year":"2011","journal-title":"Immunol Cell Biol"},{"key":"2023011114285759500_keab673-B34","first-page":"1437","article-title":"Gamma interferon is dispensable for neopterin production in vivo","volume":"12","author":"Sghiri","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"2023011114285759500_keab673-B35","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.38628","article-title":"Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type i and type ii interferon signatures","volume":"66","author":"Chiche","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2023011114285759500_keab673-B36","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1172\/JCI129301","article-title":"Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases","volume":"130","author":"AA de","year":"2020","journal-title":"J Clin Invest"},{"key":"2023011114285759500_keab673-B37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10875-016-0359-1","article-title":"Assessment of type I interferon signaling in pediatric inflammatory disease","volume":"37","author":"Rice","year":"2017","journal-title":"J Clin Immunol"},{"key":"2023011114285759500_keab673-B38","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","article-title":"Interferon target-gene expression and epigenomic signatures in health and disease","volume":"20","author":"Barrat","year":"2019","journal-title":"Nat Immunol"},{"key":"2023011114285759500_keab673-B39","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/ard.2006.061853","article-title":"Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study","volume":"66","author":"Hoppenreijs","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2023011114285759500_keab673-B40","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1002\/art.22981","article-title":"Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome","volume":"56","author":"Fall","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2023011114285759500_keab673-B41","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/art.22644","article-title":"Specific gene expression profiles in systemic juvenile idiopathic arthritis","volume":"56","author":"Ogilvie","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2023011114285759500_keab673-B42","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"Pascual","year":"2005","journal-title":"J Exp Med"},{"key":"2023011114285759500_keab673-B43","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/ard.2007.079533","article-title":"Abnormal expression of the genes involved in cytokine networks and mitochondrial function in systemic juvenile idiopathic arthritis identified by DNA microarray analysis","volume":"68","author":"Ishikawa","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2023011114285759500_keab673-B44","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/annrheumdis-2020-217470","article-title":"Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-\u03b3hyper-responsiveness and risk for macrophage activation syndrome","volume":"80","author":"Schulert","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023011114285759500_keab673-B45","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/rheumatology\/keu524","article-title":"Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-\u03b3","volume":"54","author":"Put","year":"2015","journal-title":"Rheumatology"},{"key":"2023011114285759500_keab673-B46","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.23437","article-title":"The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2023011114285759500_keab673-B47","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keab113","article-title":"A dysregulated interleukin-18\/interferon-\u03b3\/CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis","volume":"60","author":"Hinze","year":"2021","journal-title":"Rheumatology"},{"key":"2023011114285759500_keab673-B48","doi-asserted-by":"crossref","first-page":"e20014","DOI":"10.1371\/journal.pone.0020014","article-title":"Role of IL-1 beta in the development of human TH17 cells: lesson from NLPR3 mutated patients","volume":"6","author":"Lasigli\u00e8","year":"2011","journal-title":"PLoS One"},{"key":"2023011114285759500_keab673-B49","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/annrheumdis-2015-209020","article-title":"Elevated circulating levels of interferon-\u03b3 and interferon-\u03b3-induced chemokines characterize patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"76","author":"Bracaglia","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023011114285759500_keab673-B50","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1002\/art.24750","article-title":"Defective phosphorylation of interleukin-18 receptor \u00df causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis","volume":"60","author":"W De","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2023011114285759500_keab673-B51","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/art.39933","article-title":"Inflammatory gene expression profile and defective interferon-\u03b3 and Granzyme K in natural killer cells from systemic juvenile idiopathic arthritis patients","volume":"69","author":"Put","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2023011114285759500_keab673-B52","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2023011114285759500_keab673-B53","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1002\/art.34604","article-title":"The limited role of interferon-\u03b3 in systemic juvenile idiopathic arthritis cannot be explained by cellular hyporesponsiveness","volume":"64","author":"Sikora","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2023011114285759500_keab673-B54","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clim.2015.12.011","article-title":"Altered signaling in systemic juvenile idiopathic arthritis monocytes","volume":"163","author":"Macaubas","year":"2016","journal-title":"Clin Immunol"},{"key":"2023011114285759500_keab673-B55","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/01.bor.0000381996.69261.71","article-title":"Macrophage activation syndrome: advances towards understanding pathogenesis","volume":"22","author":"Grom","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"2023011114285759500_keab673-B56","first-page":"598","article-title":"How we manage hyperferritinemic sepsis related MODS\/macrophage activation syndrome\/secondary HLH","author":"Carcillo","year":"2015"},{"key":"2023011114285759500_keab673-B57","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","article-title":"Macrophage activation syndrome in the era of biologic therapy","volume":"12","author":"Grom","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2023011114285759500_keab673-B58","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/rheumatology\/kep418","article-title":"Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis","volume":"49","author":"Vastert","year":"2010","journal-title":"Rheumatology"},{"key":"2023011114285759500_keab673-B59","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1002\/art.38793","article-title":"Whole exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis","volume":"66","author":"Kaufman","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2023011114285759500_keab673-B60","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11926-014-0439-2","article-title":"Genetic defects in cytolysis in macrophage activation syndrome","volume":"16","author":"Zhang","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"2023011114285759500_keab673-B61","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/blood-2004-08-2997","article-title":"Macrophage activation syndrome: Characteristic findings on liver biopsy illustrating the key role of activated, IFN-\u03b3-producing lymphocytes and IL-6- and TNF-\u03b1-producing macrophages","volume":"105","author":"Billiau","year":"2005","journal-title":"Blood"},{"key":"2023011114285759500_keab673-B62","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1172\/JCI43157","article-title":"Repeated TLR9 stimulation results in macrophage activation syndrome\u2013like disease in mice","volume":"121","author":"Behrens","year":"2011","journal-title":"J Clin Invest"},{"key":"2023011114285759500_keab673-B63","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","article-title":"Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome","volume":"131","author":"Weiss","year":"2018","journal-title":"Blood"},{"key":"2023011114285759500_keab673-B64","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood-2015-12-684399","article-title":"Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis","volume":"127","author":"Das","year":"2016","journal-title":"Blood"},{"key":"2023011114285759500_keab673-B65","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jaci.2017.07.021","article-title":"Neutralization of IFN-\u03b3 reverts clinical and laboratory features in a mouse model of macrophage activation syndrome","volume":"141","author":"Prencipe","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2023011114285759500_keab673-B66","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood-2017-06-789552","article-title":"Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice","volume":"131","author":"Girard-Guyonvarc'h","year":"2018","journal-title":"Blood"},{"key":"2023011114285759500_keab673-B67","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/acr.21889","article-title":"Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis","volume":"65","author":"Kimura","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2023011114285759500_keab673-B68","first-page":"1","article-title":"Hypersensitivity reactions to IL-1 and IL-6 inhibitors are linked to common HLA-DRB115 alleles","author":"Hollenbach","year":"2020"},{"key":"2023011114285759500_keab673-B69","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.imbio.2014.08.011","article-title":"The Th17 pathway in the peripheral lung microenvironment interacts with expression of collagen V in the late state of experimental pulmonary fibrosis","volume":"220","author":"Fabro","year":"2015","journal-title":"Immunobiology"},{"key":"2023011114285759500_keab673-B70","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood.2019000761","article-title":"Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis","volume":"134","author":"Albeituni","year":"2019","journal-title":"Blood"},{"key":"2023011114285759500_keab673-B71","article-title":"Emapalumab (anti-interferon-gamma monoclonal antibody) in patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (sJIA) [abstract 009]","author":"De Benedetti","journal-title":"Ann Rheum Dis 2020;79:180."},{"key":"2023011114285759500_keab673-B72","doi-asserted-by":"crossref","first-page":"887","DOI":"10.21037\/atm-20-3127","article-title":"Successful treatment of secondary macrophage activation syndrome with emapalumab in a patient with newly diagnosed adult-onset Still\u2019s disease: case report and review of the literature","volume":"8","author":"Gabr","year":"2020","journal-title":"Ann Transl Med"},{"key":"2023011114285759500_keab673-B73","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/bloodadvances.2018025858","article-title":"Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections","volume":"3","author":"Lounder","year":"2019","journal-title":"Blood Adv"},{"key":"2023011114285759500_keab673-B74","doi-asserted-by":"crossref","first-page":"e28886","DOI":"10.1002\/pbc.28886","article-title":"Is neutralization of IFN-\u03b3 sufficient to control inflammation in HLH?","volume":"68","author":"Ehl","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"2023011114285759500_keab673-B75","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2023011114285759500_keab673-B76","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"2023011114285759500_keab673-B77","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"2023011114285759500_keab673-B78","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11926-018-0792-7","article-title":"JAK inhibitors in Rheumatology: implications for paediatric syndromes?","volume":"20","author":"Kerrigan","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"2023011114285759500_keab673-B79","doi-asserted-by":"crossref","first-page":"e00537","DOI":"10.1002\/prp2.537","article-title":"Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition","volume":"7","author":"Dowty","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"2023011114285759500_keab673-B80","doi-asserted-by":"crossref","first-page":"e0128757","DOI":"10.1371\/journal.pone.0128757","article-title":"Effect of JAK inhibitors on release of CXCL9, CXCL10 and CXCL11 from human airway epithelial cells","volume":"10","author":"Fenwick","year":"2015","journal-title":"PLoS One"},{"key":"2023011114285759500_keab673-B81","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Montealegre Sanchez","year":"2018","journal-title":"J Clin Invest"},{"key":"2023011114285759500_keab673-B82","doi-asserted-by":"crossref","first-page":"106480","DOI":"10.1016\/j.intimp.2020.106480","article-title":"The off-label uses profile of tofacitinib in systemic rheumatic diseases","volume":"83","author":"Zhao","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"2023011114285759500_keab673-B83","first-page":"60","article-title":"Therapeutic effect of JAK1\/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice","author":"Maschalidi","year":"2016"},{"key":"2023011114285759500_keab673-B84","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.hemonc.2017.07.002","article-title":"Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: first case report","volume":"12","author":"Sin","year":"2019","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"2023011114285759500_keab673-B85","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.3324\/haematol.2020.253781","article-title":"A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis","volume":"106","author":"Zhang","year":"2021","journal-title":"Haematologica"},{"key":"2023011114285759500_keab673-B86","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1164\/rccm.201903-0659OC","article-title":"Synergistic TLR\/IFNa\/b-signaling facilitates escape of IL-18 expression from endotoxin tolerance","volume":"201","author":"Verweyen","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2023011114285759500_keab673-B87","doi-asserted-by":"crossref","first-page":"e20182845","DOI":"10.1542\/peds.2018-2845","article-title":"Tofacitinib treatment of refractory systemic juvenile idiopathic arthritis","volume":"143","author":"Huang","year":"2019","journal-title":"Pediatrics"},{"key":"2023011114285759500_keab673-B88","article-title":"Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: a case report","author":"Bader-Meunier","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023011114285759500_keab673-B89","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/brain\/awz293","article-title":"Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib","volume":"142","author":"Sabbagh","year":"2019","journal-title":"Brain"},{"key":"2023011114285759500_keab673-B90","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jaut.2019.03.003","article-title":"Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib \u2013 A report of two cases","volume":"100","author":"Wendel","year":"2019","journal-title":"J Autoimmun"},{"key":"2023011114285759500_keab673-B91","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis \u2013 associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"2023011114285759500_keab673-B92","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ni.3818","article-title":"Type I interferons and the cytokine TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation","volume":"18","author":"Park","year":"2017","journal-title":"Nat Immunol"},{"key":"2023011114285759500_keab673-B93","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.immuni.2013.08.009","article-title":"Synergistic activation of inflammatory cytokine genes by interferon-\u03b3-induced chromatin remodeling and toll-like receptor signaling","volume":"39","author":"Qiao","year":"2013","journal-title":"Immunity"},{"key":"2023011114285759500_keab673-B94","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.4049\/jimmunol.0900592","article-title":"Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory","volume":"183","author":"Agarwal","year":"2009","journal-title":"J Immunol"},{"key":"2023011114285759500_keab673-B95","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1189\/jlb.1206763","article-title":"Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation","volume":"82","author":"Hu","year":"2007","journal-title":"J Leukoc Biol"},{"key":"2023011114285759500_keab673-B96","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.chom.2013.04.015","article-title":"Crosstalk between the type 1 interferon and nuclear factor kappa B pathways confers resistance to a lethal virus infection","volume":"13","author":"Rubio","year":"2013","journal-title":"Cell Host Microbe"},{"key":"2023011114285759500_keab673-B97","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.immuni.2010.07.001","article-title":"Nonconventional initiation complex assembly by STAT and NF-\u03baB transcription factors regulates nitric oxide synthase expression","volume":"33","author":"Farlik","year":"2010","journal-title":"Immunity"},{"key":"2023011114285759500_keab673-B98","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/cmi.2016.25","article-title":"Clash of the cytokine titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses","volume":"14","author":"Mayer-Barber","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"2023011114285759500_keab673-B99","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature13489","article-title":"Host-directed therapy of tuberculosis based on interleukin-1 and type i interferon crosstalk","volume":"511","author":"Mayer-Barber","year":"2014","journal-title":"Nature"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab673\/40499903\/keab673.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/3\/926\/48614961\/keab673.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/3\/926\/48614961\/keab673.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T12:46:30Z","timestamp":1673441190000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/3\/926\/6359838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":99,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,8,30]]},"published-print":{"date-parts":[[2022,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab673","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,1]]},"published":{"date-parts":[[2021,8,30]]}}}